"IMP"@en . "Imipenem"@en . "74431-23-5"@en . "20% binds to plasma proteins"@en . "Imipenem is not effectively absorbed from the gastrointestinal tract and therefore must be administered parenterally."@en . "approved"@en . "1 hour"@en . . "Maurizio Zenoni, \"Imipenem production process.\" U.S. Patent US20020095034, issued July 18, 2002."@en . . . . . . . "Imipemide"@en . "(5R,6S)-3-(2-Formimidoylamino-ethylsulfanyl)-6-((R)-1-hydroxy-ethyl)-7-oxo-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid"@en . "N-formimidoylthienamycin"@en . "(5R,6S)-3-((2-(Formimidoylamino)ethyl)thio)-6-((R)-1-hydroxyethyl)-7-oxo-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid"@en . . . . "N-Formimidoyl thienamycin"@en . . . . " "@en . . "Imipenem acts as an antimicrobial through the inhibition of cell wall synthesis of various gram-positive and gram-negative bacteria. This inhibition of cell wall synthesis in gram-negative bateria is attained by binding to pencillin binding proteins (PBPs). In E. coli and selected strains of P. aeruginosa, imipenem has shown to have the highest affinity to PBP-2, PBP-1a, and PBP-1b. This preferential binding to PBP-2 and PBP-1b results in the direct conversion of the individual cell to a spheroblast, which leads to rapid cell lysis and death without filament formation."@en . . "Imipenem, n-formimidoyl thienamycin"@en . . "Imipenemum"@en . . "# Kattan JN, Villegas MV, Quinn JP: New developments in carbapenems. Clin Microbiol Infect. 2008 Dec;14(12):1102-11. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19076841 # Pastel DA: Imipenem-cilastatin sodium, a broad-spectrum carbapenem antibiotic combination. Clin Pharm. 1986 Sep;5(9):719-36. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/3530614 # Clissold SP, Todd PA, Campoli-Richards DM: Imipenem/cilastatin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1987 Mar;33(3):183-241. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/3552595 # Buckley MM, Brogden RN, Barradell LB, Goa KL: Imipenem/cilastatin. A reappraisal of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1992 Sep;44(3):408-44. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/1382937 # Richerson MA, Ambrose PG, Quintiliani R, Nightingale CH: Formulary review of the carbapenems: comparison of imipenem/cilastatin and meropenem. Conn Med. 1998 Mar;62(3):165-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9573653 # Birnbaum J, Kahan FM, Kropp H, MacDonald JS: Carbapenems, a new class of beta-lactam antibiotics. Discovery and development of imipenem/cilastatin. Am J Med. 1985 Jun 7;78(6A):3-21. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/3859213 # Hellinger WC, Brewer NS: Imipenem. Mayo Clin Proc. 1991 Oct;66(10):1074-81. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/1921491 # Kahan FM, Kropp H, Sundelof JG, Birnbaum J: Thienamycin: development of imipenen-cilastatin. J Antimicrob Chemother. 1983 Dec;12 Suppl D:1-35. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/6365872"@en . . . "Imipenem"@en . . . . . . "Enteric bacteria and other eubacteria"@en . . . "(5R,6S)-6-((R)-1-Hydroxyethyl)-3-(2-(iminomethylamino)ethylthio)-7-oxo-1-azabicyclo(3.2.0)hept-2-ene-2-carbonsaeure"@en . . "For the treatment of bacterial infections caused by susceptible bacteria."@en . . . "Imipenem anhydrous"@en . . . . . . "Semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to beta-lactamases. Clinical studies have demonstrated high efficacy in the treatment of infections of various body systems. Its effectiveness is enhanced when it is administered in combination with cilastatin, a renal dipeptidase inhibitor. [PubChem]"@en . . . . . . . . .